Achillion Pharmaceuticals (NASDAQ: ACHN) has recently received a number of price target changes and ratings updates:

  • 9/14/2017 – Achillion Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Achillion has no approved product in its portfolio and focuses on developing small molecule therapeutics to treat infectious and complement-mediated diseases. The complement-mediated space is highly crowded as biotech companies are working on bringing these treatments to market. However this area has potential for commercial opportunity. In a major setback, J&J terminated its HCV agreement and Achillion lost a strong and experienced partner and source of funds. The HCV market represents huge commercial potential. Moreover, Merck is also developing similar therapy for HCV genotype infections. However, the company has shown progress in developing Factor D inhibitors. Meanwhile, shares have underperformed the industry so far this year.”
  • 9/12/2017 – Achillion Pharmaceuticals had its price target lowered by analysts at Ladenburg Thalmann Financial Services from $9.00 to $6.50. They now have a “buy” rating on the stock.
  • 9/12/2017 – Achillion Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $4.00 price target on the stock, down previously from $5.00.
  • 9/11/2017 – Achillion Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/16/2017 – Achillion Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/11/2017 – Achillion Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Achillion generated no revenue in Q2 while loss was in line with estimates. The company has no approved product in its portfolio and focuses on developing small molecule therapeutics to treat infectious and complement-mediated diseases. The complement-mediated space is highly crowded as biotech companies are working on bringing these treatments to market. However this area has potential for commercial opportunity. Meanwhile, Achillion’s deal with J&J for its HCV portfolio provides the company with a strong and experienced partner and will also bring in funds. The HCV market also represents huge commercial potential. However, Merck is also developing similar therapy for HCV genotype infections. Also, we remain concerned about the early-stage nature of the complement Factor D pipeline and dependence on collaboration for funds.”
  • 8/10/2017 – Achillion Pharmaceuticals was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $5.00 price target on the stock.
  • 8/9/2017 – Achillion Pharmaceuticals had its price target lowered by analysts at Chardan Capital from $5.00 to $4.00. They now have a “neutral” rating on the stock.
  • 8/9/2017 – Achillion Pharmaceuticals was given a new $7.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 8/5/2017 – Achillion Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/25/2017 – Achillion Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2017 – Achillion Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Achillion has no approved product in its portfolio and focuses on developing small molecule therapeutics to treat infectious and complement-mediated diseases. The complement-mediated space is highly crowded as biotech companies are working on bringing these treatments to market. However this area has potential for commercial opportunity. Meanwhile, Achillion’s deal with J&J for its HCV portfolio provides the company with a strong and experienced partner and will also bring in funds. The HCV market also represents huge commercial potential.However, Merck is also developing similar therapy for HCV genotype infections. Also, we remain concerned about the early-stage nature of the complement Factor D pipeline and dependence on collaboration for funds. Estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in recent quarters.”

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 3.57 on Friday. The stock’s market cap is $488.58 million. Achillion Pharmaceuticals, Inc. has a 52-week low of $3.15 and a 52-week high of $9.19. The firm’s 50-day moving average price is $4.52 and its 200 day moving average price is $4.20.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same period last year, the company posted ($0.14) EPS. Equities analysts predict that Achillion Pharmaceuticals, Inc. will post ($0.66) earnings per share for the current year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Ratings for Achillion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.